A Phase I pharmacokinetic and pharmacodynamic study of PX-12, a novel inhibitor of thioredoxin-1, in patients with advanced solid tumors.
about
A phase I trial of PX-12, a small-molecule inhibitor of thioredoxin-1, administered as a 72-hour infusion every 21 days in patients with advanced cancers refractory to standard therapy.Angiogenesis inhibitors: current strategies and future prospects.Thioredoxin-1 inhibitor PX-12 induces human acute myeloid leukemia cell apoptosis and enhances the sensitivity of cells to arsenic trioxideNuclear expression of thioredoxin-1 in the invasion front is associated with outcome in patients with gallbladder carcinomaFungal antioxidant pathways promote survival against neutrophils during infection.PX-12-induced HeLa cell death is associated with oxidative stress and GSH depletion.A phase IB trial of 24-hour intravenous PX-12, a thioredoxin-1 inhibitor, in patients with advanced gastrointestinal cancersHypoxia-inducible factor inhibitors: a survey of recent patented compounds (2004 - 2010).Peroxiredoxins, gerontogenes linking aging to genome instability and cancer.Physical interaction between human ribonucleotide reductase large subunit and thioredoxin increases colorectal cancer malignancy.Clinically Evaluated Cancer Drugs Inhibiting Redox Signaling.PX-12 induces apoptosis in Calu-6 cells in an oxidative stress-dependent manner.Chloroethyl urea derivatives block tumour growth and thioredoxin-1 nuclear translocation.Increased mitochondrial thioredoxin 2 potentiates N-ethylmaleimide-induced cytotoxicity.Binding of phenothiazines into allosteric hydrophobic pocket of human thioredoxin 1.Selective inhibition of extracellular thioredoxin by asymmetric disulfides.Thioredoxin-1 protects against androgen receptor-induced redox vulnerability in castration-resistant prostate cancer.A randomized phase II study of PX-12, an inhibitor of thioredoxin in patients with advanced cancer of the pancreas following progression after a gemcitabine-containing combination.Baseline [(18)F]FMISO μPET as a Predictive Biomarker for Response to HIF-1α Inhibition Combined with 5-FU Chemotherapy in a Human Colorectal Cancer Xenograft Model.Upregulation of connexin43 contributes to PX-12-induced oxidative cell death.Hypoxia-regulated gene network in drug resistance and cancer progression.
P2860
Q34001569-E8BD0FAD-7535-4776-B562-C4FF7EB82BCFQ34056376-214E98E6-9982-430F-980C-E21B0EA955CDQ34121354-654422D4-F4BD-4651-AC8E-5CD6E2BF90BCQ36288778-F0E30D50-13EC-4E96-86B5-E949BF893500Q36499477-6C101C47-BC17-4BA3-8FBF-B0CFB76DDB6CQ37325166-5EBDCFD0-5503-4376-A087-7206371761DBQ37706505-6D83B4A3-8975-4344-87EC-2F3A3A355F7CQ37826426-80D7D39A-8451-49A5-8B9B-67DDBCBB299CQ38044329-0CAB5104-359C-423E-9335-7ED2394E4FC3Q38707613-34AFB020-B9EA-4956-8B47-D9A65A966733Q38777221-3DE17D40-5A97-41E1-B7E3-6A4F2C06910EQ38940920-16AA5EFE-5EA8-491A-8CF4-36678BDEDF35Q39631909-78993757-3E9C-4268-836F-4B00382419A5Q39986849-CFC8107B-647D-4DD2-B140-07501B71A3C7Q40049464-4030E4AE-8814-4D42-881B-C67218EAD651Q43246200-9564E2A4-21DF-4212-A5A3-224D06C053E3Q46271330-C97AB936-971B-4E4E-B9AB-EE20F0479A01Q50553669-86691324-39FE-4D87-8F42-610DDD279CE6Q51559766-F6BEF2C9-171D-426E-9E71-7AD52C9C5FC4Q51600585-F2456608-E001-46EA-B386-8824C288B4FDQ54354000-C228052C-5EE1-452D-AA0B-0BE11FD14354
P2860
A Phase I pharmacokinetic and pharmacodynamic study of PX-12, a novel inhibitor of thioredoxin-1, in patients with advanced solid tumors.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
A Phase I pharmacokinetic and ...... ts with advanced solid tumors.
@en
A Phase I pharmacokinetic and ...... ts with advanced solid tumors.
@nl
type
label
A Phase I pharmacokinetic and ...... ts with advanced solid tumors.
@en
A Phase I pharmacokinetic and ...... ts with advanced solid tumors.
@nl
prefLabel
A Phase I pharmacokinetic and ...... ts with advanced solid tumors.
@en
A Phase I pharmacokinetic and ...... ts with advanced solid tumors.
@nl
P2093
P1476
A Phase I pharmacokinetic and ...... ts with advanced solid tumors.
@en
P2093
Amanda Baker
Catherine A Cordova
D Lynn Kirkpatrick
David Friedland
H-H Sherry Chow
Ramesh K Ramanathan
Steven P Stratton
Sylvan B Green
Tomislav Dragovich
P304
P356
10.1158/1078-0432.CCR-06-2250
P407
P577
2007-04-01T00:00:00Z